Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Moodys
Federal Trade Commission
Mallinckrodt
Fish and Richardson
US Department of Justice

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: RE46856

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE46856 protect, and when does it expire?

Patent RE46856 protects ALIQOPA and is included in one NDA.

This patent has forty-nine patent family members in forty-one countries.

Summary for Patent: RE46856
Title:Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Inventor(s): Hentemann; Martin (Carlisle, MA), Wood; Jill (Fort Collins, CO), Scott; William (Guilford, CT), Michels; Martin (Koln, DE), Campbell; Ann-Marie (Monroe, CT), Bullion; Ann-Marie (Milford, CT), Rowley; Bruce R. (New Hope, PA), Redman; Aniko (Durham, NC)
Assignee: Bayer Intellectual Property GMBH (Monheim, DE)
Application Number:15/398,916
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent RE46856

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE46856

PCT Information
PCT FiledDecember 05, 2007PCT Application Number:PCT/US2007/024985
PCT Publication Date:June 12, 2008PCT Publication Number: WO2008/070150

International Family Members for US Patent RE46856

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064106 ➤ Sign Up
Australia 2007328008 ➤ Sign Up
Brazil PI0720178 ➤ Sign Up
Canada 2671614 ➤ Sign Up
Chile 2007003508 ➤ Sign Up
China 101631464 ➤ Sign Up
China 105254634 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Argus Health
Cantor Fitzgerald
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.